CONTEXT: Atherosclerotic cardiovascular diseases, including coronary heart disease (CHD), carotid artery stenosis (CAS), peripheral artery disease (PAD), and abdominal aortic aneurysm (AAA), affect millions of U.S. adults and are leading causes of morbidity and mortality. There is some uncertainty regarding the utility of certain screening tests for prevention of cardiovascular morbidity and mortality. EVIDENCE ACQUISITION: Current guidelines and studies pertaining to CHD, CAS, PAD, and AAA screening in the adult population were reviewed. EVIDENCE SYNTHESIS: CHD risk can be estimated by the Framingham Risk Score (FRS), which is valuable in identifying high-risk asymptomatic adults who may benefit from preventive treatments. There is moderate certainty that the benefits of screening do not outweigh the harms for individuals with asymptomatic CAS. The potential harms associated with routine PAD screening in asymptomatic adults are also likely to exceed benefits. Ultrasonography is a safe, noninvasive, and reliable screening test used to identify AAAs for treatment in men aged >65 years who have ever smoked. CONCLUSIONS: American College of Preventive Medicine (ACPM) recommends CHD risk assessment using the FRS to guide risk-based therapy. ACPM does not recommend routine screening of the general adult population using electrocardiogram, exercise-stress testing, computed tomography scanning, ankle-brachial index, carotid intima medial thickness, or emerging risk factors, including high-sensitivity C-reactive protein (hs-CRP). ACPM does not recommend routine screening of the general adult population for CAS or PAD. ACPM recommends one-time AAA screening in men aged 65-75 years who have ever smoked. Routine AAA screening in women is not recommended.
CONTEXT: Atherosclerotic cardiovascular diseases, including coronary heart disease (CHD), carotid artery stenosis (CAS), peripheral artery disease (PAD), and abdominal aortic aneurysm (AAA), affect millions of U.S. adults and are leading causes of morbidity and mortality. There is some uncertainty regarding the utility of certain screening tests for prevention of cardiovascular morbidity and mortality. EVIDENCE ACQUISITION: Current guidelines and studies pertaining to CHD, CAS, PAD, and AAA screening in the adult population were reviewed. EVIDENCE SYNTHESIS: CHD risk can be estimated by the Framingham Risk Score (FRS), which is valuable in identifying high-risk asymptomatic adults who may benefit from preventive treatments. There is moderate certainty that the benefits of screening do not outweigh the harms for individuals with asymptomatic CAS. The potential harms associated with routine PAD screening in asymptomatic adults are also likely to exceed benefits. Ultrasonography is a safe, noninvasive, and reliable screening test used to identify AAAs for treatment in men aged >65 years who have ever smoked. CONCLUSIONS: American College of Preventive Medicine (ACPM) recommends CHD risk assessment using the FRS to guide risk-based therapy. ACPM does not recommend routine screening of the general adult population using electrocardiogram, exercise-stress testing, computed tomography scanning, ankle-brachial index, carotid intima medial thickness, or emerging risk factors, including high-sensitivity C-reactive protein (hs-CRP). ACPM does not recommend routine screening of the general adult population for CAS or PAD. ACPM recommends one-time AAA screening in men aged 65-75 years who have ever smoked. Routine AAA screening in women is not recommended.
Authors: Shuhei Tara; Hirotsugu Kurobe; Kevin A Rocco; Mark W Maxfield; Cameron A Best; Tai Yi; Yuji Naito; Christopher K Breuer; Toshiharu Shinoka Journal: Atherosclerosis Date: 2014-10-17 Impact factor: 5.162
Authors: D S Cross; C A McCarty; E Hytopoulos; M Beggs; N Nolan; D S Harrington; T Hastie; R Tibshirani; R P Tracy; B M Psaty; R McClelland; P S Tsao; T Quertermous Journal: Curr Med Res Opin Date: 2012-11 Impact factor: 2.580
Authors: Nathan K Itoga; Hataka R Minami; Meenadachi Chelvakumar; Keon Pearson; Matthew M Mell; Eran Bendavid; Douglas K Owens Journal: Vasc Med Date: 2018-01-18 Impact factor: 3.239
Authors: Jenni Murray; Grania Fenton; Stephanie Honey; Ana Claudia Bara; Kate Mary Hill; Allan House Journal: BMC Cardiovasc Disord Date: 2013-07-06 Impact factor: 2.298
Authors: Peter Lanzer; Manfred Boehm; Victor Sorribas; Marc Thiriet; Jan Janzen; Thomas Zeller; Cynthia St Hilaire; Catherine Shanahan Journal: Eur Heart J Date: 2014-04-16 Impact factor: 29.983